Can You Stay on a Low Dose of Wegovy? What the FDA Label Allows

If you feel like the dose you are on is working and you would rather not push higher, the FDA label is more accommodating than most people assume. For weight reduction in adults, the Wegovy prescribing information states that the maintenance dosage is “either 1.7 mg or 2.4 mg (recommended)” once weekly, and instructs prescribers to “consider treatment response and tolerability when selecting the maintenance dosage”^[1]. In other words 1.7 mg is a named destination, not merely a rung on the ladder. That is a genuinely different answer from “you must reach 2.4 mg,” which is what a lot of people are told. What the label does not do is bless stopping at 0.25, 0.5 or 1 mg indefinitely — those are escalation steps, and the efficacy data behind the approval come from the higher doses. Here is what the label actually says, what the trials showed at each dose, and the honest trade-off.

The honest summary

• 1.7 mg is a labeled maintenance dose for weight reduction. Verbatim: “The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly”^[1]. Staying at 1.7 mg is therefore on-label, not off-label.
• 2.4 mg is still the recommended one. The parenthetical “(recommended)” is doing real work — it signals the dose the pivotal efficacy data are built around. Choosing 1.7 mg is a legitimate option, not an equivalent one.
• The doses below 1.7 mg are escalation steps, not destinations. The label's schedule runs 0.25 mg for weeks 1–4, 0.5 mg for 5–8, 1 mg for 9–12, 1.7 mg for 13–16, then maintenance from week 17^[1]. It does not describe 0.5 or 1 mg as a maintenance option for weight reduction.
• If you are struggling to tolerate a step, the label allows waiting. Verbatim: “If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks”^[1]. Slowing down is explicitly anticipated.
• There is now a higher ceiling too. For patients who tolerate 2.4 mg for at least 4 weeks and need more, the label permits increasing to a maximum of 7.2 mg once weekly^[1] — a dose tested in the STEP UP T2D phase 3b trial (Lingvay 2025^[3]).
• Stopping is different from staying low. In the STEP 4 randomised withdrawal trial, people switched to placebo after reaching maintenance regained weight, while those who continued kept losing (Rubino 2021^[2]). Dropping the dose to zero has a well-measured consequence.

What the label actually says

The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly. … Consider treatment response and tolerability when selecting the maintenance dosage.

— WEGOVY prescribing information, Dosage and Administration (DailyMed)[[cite:1]]

Two things are worth pulling out of that sentence. The first is that the label offers a genuine choice between two maintenance doses rather than a single target. The second is the instruction to weigh treatment response and tolerability — which is the label explicitly inviting the conversation many patients assume they are not allowed to have. If you are losing weight satisfactorily at 1.7 mg and the higher dose brings side effects you would rather avoid, that trade-off is precisely what the sentence contemplates.

It is also worth knowing that the same structure appears for the other indications, but with different answers. For cardiovascular risk reduction in adults the maintenance dosage is likewise “either 2.4 mg (recommended) or 1.7 mg once weekly”^[1]. So the flexibility is not unique to weight management.

The escalation schedule, and why the lower steps are not destinations

The label is explicit that the escalation exists “to reduce the risk of gastrointestinal adverse reactions”^[1] — the ramp is a tolerability device, not a therapeutic strategy in itself. That is the core reason 0.25, 0.5 and 1 mg are not offered as places to stop for weight reduction: they were designed to get you comfortably to a dose that works, and the efficacy evidence supporting approval was generated at the top of the ladder.

What happens if you stop instead of staying low

The cleanest evidence on this comes from STEP 4 (Rubino 2021^[2]), published in JAMA. Participants were escalated to 2.4 mg over a 20-week run-in, then randomised either to continue semaglutide or to switch to placebo for the following 48 weeks. The design is what makes it useful: everyone had already reached maintenance, so the trial isolates the effect of continuing versus not. Those who continued kept losing weight; those switched to placebo regained a substantial share of what they had lost.

That result is about stopping, not about dose reduction, and it should not be over-read as proof that 1.7 mg fails — no trial randomised people to 1.7 mg versus 2.4 mg maintenance and followed them for a year. But it does establish the direction of travel when drug exposure falls, which is worth holding in mind when weighing a lower maintenance dose. For a fuller treatment see our piece on why people stop GLP‑1s.

Questions worth taking to your prescriber

1. Am I responding well enough at this dose? The label's own criterion is treatment response, so bring your actual numbers rather than a general sense of how it is going.
2. What specifically am I trying to avoid by not going up? Nausea that has not settled is a different argument from anticipating side effects you have not had.
3. Is my plateau a dose problem or something else? Plateaus have several causes — see our plateau guide before assuming the answer is more milligrams.
4. If I stay at 1.7 mg, what would change your mind later? Agreeing the trigger in advance makes the decision reviewable rather than permanent.
5. What does my supply and cost situation look like at each dose? This is a real input, and pretending otherwise helps nobody.

The bottom line

You can stay on 1.7 mg. The FDA label names it as a maintenance dosage for weight reduction in adults and tells prescribers to pick between it and 2.4 mg on response and tolerability^[1]. What you cannot claim label support for is settling permanently on 0.25, 0.5 or 1 mg — those are escalation steps built to manage side effects on the way up. And the STEP 4 data are a reminder that reducing exposure to zero has a measurable cost (Rubino 2021^[2]). The productive move is to bring the label's own two criteria, response and tolerability, to your prescriber and make the decision on those terms.